SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Milan who wrote (4446)1/9/1998 8:20:00 PM
From: MisterED  Respond to of 23519
 
It was announced today that Vivus is raising prices of Muse
by 4% effective January 15th. This to me is good news for two
reasons. It shows confidence in their product and its market,
and hopefully will add to their earnings, or at least cover
additional costs in connection with all their new promotions
and production facilities. To save money this would be a good
time to stock up on both Muse and Vivus shares<ggg>.



To: Milan who wrote (4446)1/10/1998 5:43:00 AM
From: blankmind  Read Replies (1) | Respond to of 23519
 
-- Thanks for the anecdotal story. Because demand for MUSE is so strong, new production coming on line, price increase, and the fact that MUSE dominates the market, the price of VVUS shares should go up shortly.

-- Also, given the fact that the refill rate continues to grow, I think the Pfizer product - Viagra - will not seriously hurt sales of MUSE. Note: whenever and if Viagra ever gets approved.

Out.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News